Drugs / HFB301001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05229601 | Apr 2022 → May 2024 | head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, renal cell carcinoma +2 | HiFiBiO Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | HiFiBiO Therapeutics | Regulatory HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001 hifibio.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-05 | HiFiBiO Therapeutics | HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO Congress hifibio.com ↗ |
| 2022-01-10 | HiFiBiO Therapeutics | HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001 hifibio.com ↗ |
| 2021-04-12 | HiFiBiO Therapeutics | Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody hifibio.com ↗ |
| 2020-07-03 | HiFiBiO Therapeutics | HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy hifibio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFB301001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05229601 ↗ |
| Action | Activate | “HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.” PMID 41912269 ↗ Mar 2026 |
| Route | Intravenous | “Participants will receive HFB301001 via intravenous infusions” NCT05229601 ↗ |